US › Healthcare

Altimmune Inc (ALT)

US · Healthcare · Biotechnology

$2.20-6.78%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-22.8M

EPS

$-0.12

EPS estimate

$-0.15

EPS came in at -0.12 against a street estimate of -0.15 — a beat of 20.0%.

Key statistics

Market cap

$427.9M

Forward P/E

8.2

P/B

1.31

Book value

$2.44

EPS (TTM)

$-0.76

52-week high

$6.44

52-week low

$2.17

50-day MA

$3.00

200-day MA

$3.37

Beta

0.06

Analyst view

Analysts rate Altimmune Inc a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $17.11.

Shareholding

Insiders

0.43%

Institutions

77.86%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.48%
Deep Track Capital, LP	9.90%
State Street Corp	6.22%
TCG Crossover Management, LLC	5.14%
Vanguard Capital Management, LLC	4.20%
Vanguard Portfolio Management, LLC	3.77%
Marshall Wace Asset Management Ltd	3.52%
Viking Global Investors LP	3.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Altimmune Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.